Page last updated: 2024-08-24

azelnidipine and Neoplasms

azelnidipine has been researched along with Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Chen, J; Dong, Q; Gao, Y; Jiao, L; Qian, Y; Qiu, L; Sun, Y; Wang, H; Wu, Y; Zhai, W; Zhao, W; Zheng, WV; Zhou, X	1

Other Studies

1 other study(ies) available for azelnidipine and Neoplasms

Article	Year
Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy. Biomolecules, 2021, 05-10, Volume: 11, Issue:5 Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; CD47 Antigen; Cell Line, Tumor; Cricetinae; Dihydropyridines; Disease Models, Animal; Drug Repositioning; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Immunotherapy; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Targeted Therapy; Neoplasms; Receptors, Immunologic; Receptors, Virus; T-Lymphocytes	2021

Article

Year

Repositioning Azelnidipine as a Dual Inhibitor Targeting CD47/SIRPα and TIGIT/PVR Pathways for Cancer Immuno-Therapy.

Biomolecules, 2021, 05-10, Volume: 11, Issue:5

Topics: Animals; Azetidinecarboxylic Acid; Calcium Channel Blockers; CD47 Antigen; Cell Line, Tumor; Cricetinae; Dihydropyridines; Disease Models, Animal; Drug Repositioning; Gene Expression Regulation, Neoplastic; Humans; Immunity, Innate; Immunotherapy; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Molecular Targeted Therapy; Neoplasms; Receptors, Immunologic; Receptors, Virus; T-Lymphocytes

2021